New hope for HER2 breast cancer: experimental combo faces standard care in major trial

This study tests whether a new combination of drugs (KN026 plus HB1801 and chemotherapy) works better than the current standard treatment (trastuzumab, pertuzumab, and chemo) for people with HER2-positive breast cancer that has been surgically removed. About 1800 adults with cancer spread to lymph nodes will take part. The goal is to see if the new combo delays cancer return or death.